These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24479980)

  • 41. Anti-adhesion molecules: is gut specificity the key for a good safety profile?
    Allen PB
    Curr Drug Deliv; 2012 Jul; 9(4):333-7. PubMed ID: 22762276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
    Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Complexity of alpha E beta 7 Blockade in Inflammatory Bowel Diseases.
    Smids C; Horjus Talabur Horje CS; van Wijk F; van Lochem EG
    J Crohns Colitis; 2017 Apr; 11(4):500-508. PubMed ID: 27660340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
    Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
    Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Underappreciated Role of Secretory IgA in IBD.
    Bamias G; Kitsou K; Rivera-Nieves J
    Inflamm Bowel Dis; 2023 Aug; 29(8):1327-1341. PubMed ID: 36943800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
    Rivera-Nieves J
    Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
    Peng JC; Shen J; Ran ZH
    J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
    Smith MA; Mohammad RA
    Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New drug therapies on the horizon for IBD.
    Perrier C; Rutgeerts P
    Dig Dis; 2012; 30 Suppl 1():100-5. PubMed ID: 23075877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
    Luthra P; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1227-36. PubMed ID: 25903741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New molecules in the treatment of inflammatory bowel disease].
    Chaparro M; Gisbert JP
    Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Zundler S; Becker E; Schulze LL; Neurath MF
    Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting T-cell migration in inflammatory bowel disease.
    Marsal J; Agace WW
    J Intern Med; 2012 Nov; 272(5):411-29. PubMed ID: 22946654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.
    Mosli MH; Rivera-Nieves J; Feagan BG
    Drugs; 2014 Mar; 74(3):297-311. PubMed ID: 24452878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting integrins and adhesion molecules to combat inflammatory bowel disease.
    Marafini I; Sedda S; Pallone F; Monteleone G
    Inflamm Bowel Dis; 2014 Oct; 20(10):1885-9. PubMed ID: 25215614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.